1 / 12

Diabetes Clinical and Translational Research: Rewards and Challenges

Diabetes Clinical and Translational Research: Rewards and Challenges. Ruth S. Weinstock MD PhD Medical Director, Joslin Diabetes Center and Clinical Research Unit Professor of Medicine and Chief, Endocrinology, Diabetes and Metabolism SUNY Upstate Medical University Syracuse NY

aletta
Download Presentation

Diabetes Clinical and Translational Research: Rewards and Challenges

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Diabetes Clinical and Translational Research:Rewards and Challenges Ruth S. Weinstock MD PhD Medical Director, Joslin Diabetes Center and Clinical Research Unit Professor of Medicine and Chief, Endocrinology, Diabetes and Metabolism SUNY Upstate Medical University Syracuse NY October 24, 2011

  2. Disclosures Research funding: NIH/NIDDK, Helmsley Charitable Trust Speaker bureaus/honoraria: none Multicenter clinical trials: Diamyd, Eli Lilly, Pfizer, Ultradian Diagnostics Inc., GlaxoSmithKline, Macrogenics, MiniMed

  3. Prevention and Management of Diabetes:Types of Clinical Research • Initiation: • Investigator vs. non investigator • Focus: • Medications • Devices • Behavioral interventions • Epidemiology • Quality of life • Health services • Others

  4. Sponsors Federal: NIH, DOD, VA, CMS, other Foundations/non-for-profits (ADA, JDRF, others) State health departments (usually limited funding and indirect cost recovery) Industry: Phase I: evaluate safety, determine dose, side effects (n=20-80) Phase II: evaluate effectiveness, further safety (n=100-300) Phase III: confirm effectiveness, monitor side effects, compare to standard Rx (n=1000-3000) Phase IV: collect more information re: risks, benefits, uses Hybrids

  5. Why Participate? • Intellectual benefits: contribute to understanding of disease and development of new therapies • Academic rewards • Early experience with new treatments • Free services/medications to the needy

  6. Requirements • Trained staff • For subjects: benefits > risks • Adherence to GCP (Good Clinical Practice) principles • Compliance with federal regulations (Protection of Human Subjects) • IRB approval • Ability to meet recruitment and retention goals • Meticulous record keeping • Sufficient funding (careful budgeting!) • Dependent upon study: EMR, statistical/study design support, specific facilities eg Clinical Research Unit • Must follow protocol exactly!

  7. Considerations for Participate in Clinical Trials • Do you have the required? • Patient population • Collaborators • Ancillary services • Equipment • Facilities (e.g. inpatient vs outpatient, pantry, pharmacy, laboratory, specimen processing) • Trained, dedicated staff • Time (P.I. etc) • Other • Is budget sufficient? • Duration of study?

  8. Current Diabetes Grants at Upstate Medical University NIH (n=6) Industry-sponsored multicenter clinical trials (n=13) Foundation (Type 1 Diabetes Exchange) NYS Dept of Health Diabetes Center of Excellence (support community outreach, professional education and pilot projects e.g. school telemedicine)

  9. Upstate Clinical Diabetes NIH Grants Investigator-initiated: SHINE, DSP Support salaries (% effort), other costs Highest indirect cost recovery Most difficult to obtain Greatest intellectual/academic gratification SBIR (Small Business Innovation Research) Partner with small business (new CGMS device) Joint federal and industry sponsorship Multicenter trials: TODAY, TrialNet Funding: traditional (% effort) or accrual based

  10. Diabetes Industry-Sponsored Multicenter Clinical Trials • Usually little input from investigators re: design • Competitive enrollment • Funding: based on recruitment and retention • Indirect cost recovery: 30—50% of NIH • Need to meet enrollment and retention goals • May be discontinued at any time • Need significant number of subjects to break even

  11. So…Should We Participate? Carefully consider all factors (budget, patient population, staffing, other support) before committing Once committed, need to perform to expectations ENJOY!

  12. THANK YOU!

More Related